Нарушения фосфорно-кальциевого обмена при хронической болезни почек III–V стадий


Л.Ю. Милованова, Ю.С. Милованов, Л.В. Козловская

ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, Москва
Обсуждаются механизмы развития и методы лечения нарушений фосфорно-кальциевого обмена при хронической болезни почек III–V стадий.

Литература


1. National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am. J. Kidney Dis. 2003 (suppl. 3); 42: S1–S202.
2. Ермоленко В.М. Хроническая почечная недостаточность. Нефрология: национальное руководство. Под ред. Н.А. Мухина. М.: ГЕОТАР-Медиа. 2009; 579–629.
3. Hruska K. A., Mathew S., Lund R. et al. Hyperphosphatemia of Chronic Kidney Disease. Kidney Int. 2008; 74(2): 148–157.
4. Gutierrez O., Isacova T., Rhee E. et al Fibroblast Growth factor-23 Mitigates Hyperphosphatemia But Accentuates Calcitriol Deficiency in chronic Kidney Disease. Kidney Int. 2005; 16: 2205–2215.
5. Fucumoto S. Physiological regulationand Disorders of Phosphate metabolism – Pivotal Role of Fibroblast Growth factor-23. Inter. Med. 2008; 47: 337–343.
6. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32: S112–S119.
7. Parfey P.S. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol. Dial. Transplant. 2000; 5(Suppl 5): 58–68.
8. London G. M. Cardiovascular risk in end-stage renal disease:vascular aspects. Nephrol. Dial. Transplant. 2000; 15(Suppl 5): 97–104.
9. Coresh J., Selvin E., Stevens L.A. et al. Prevalence of Chronic Kidney Disease in the United States. J. Am. Med. Assoc. 2007; 298:2038–2047.
10. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New. Engl. J. Med. 2004; 351:1296–1305.
11. Block G.A., Hulbert-Shearon T.E., Levin N.W. et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998;.31:607–617.
12. Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005;16:520–528.
13. Slinin Y., Foley R.N., Collins A.J. Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study. J. Am. Soc. Nephrol. 2005; 16:1788–1793.
14. Marchais S.J., Metivier F., Guerin A.P. et al. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol. Dial. Transplant. 1999; 14: 2178–2183.
15. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int.2007; 71: 438–441.
16. Craver L., Marco M.P., Martinez I. et al. Mineral metabolism parameters throughout chronic kidney disease stages 1–5-achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007; 22: 1171–1176.
17. Liu S., Tang W., Zhou J. et al. Fibroblast Growth Factor 23. Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D. J. Am. Soc. Nephrol. 2006;17:1305–1315.
18. Земченков А.Ю., Герасимчук Р.П. Активаторы рецепторов витамина D и сосудистая кальцификация (обзор литературы). Нефрол. диал. 2009; 4(11): 276–292.
19. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрол. диал. 2002; 2(4):113–117.
20. Wang L., Jerosch-Herold M., Jacobs J. et al. Coronary Artery Calcification and Myocardial Perfusion in Asymptomatic Adults: The MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2006; 48: 1018–1026.
21. Pletcher M.J., Tice J.A., Pignone M. et al. Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events: A Systematic Review and Meta-analysis. Arch. Int. Med. 2004; 164: 128.5–1292.
22. Davies MR., Lund R.J., Hruska K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J. Am. Soc. Nephrol. 2003; 14: 1559–1567.
23. Davies M.R., Lund R.J., Mathew S. et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J. Am. Soc. Nephrol. 2005; 16: 917–928.
24. Isakova T., Gutierrez O.M. Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in early CKD. J. Am. Soc. Nephrol. 2008; 19(3): 615–623.
25. Nishimura M., Tsukamoto K., Tamaki N. et al. Risk stratification for cardial death in hemodialysis patients without obstructive coronary artery disease. Kidney Int. 2011; 79: 363–371.
26. Razzaque M.S. FGF23-mediated regulation of systemic phosphate homeostasis Klotho an essential player? Am. J. Physiol. Renal Physiol. 2008; 19(11): 1–27.
27. Pande S., Ritter C.S., Rothstein M. et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006; 104: 23–32.
28. Razzaque M.S. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol. Dial. Transplant. 2009; 24(1): 4–7. 29. Gutierrez O.M. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. Circulation. 2009; 119: 2545–2552.
30. Jean G. High levels of serum FGF-23 are associated with increased mortality in long haemodialysis patients. N.D.T. 2009 24(9); 2792–2796.
31. Gutierrez O.M., Mannstadt M., Isakova T. et al. Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl. J. Med. 2008; 359: 584–592.
32. Gutierrez O.M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 2205–2215.
33. Gutierrez O.M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584–592.
34. Kawata T. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 2007; 18:2683–2688.
35. Boekel G. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur. J. Endocrinol. 2008; 158:431–437.
36. Fang M.A., Glackin C.A., Sadhu A. et al. Transcriptional regulation of alpha 2(I) collagen gene expression by fibroblast growth factor-2 in MC3T3-E1 osteoblast-like cells. J. Cell. Biochem. 2001; 80: 550–559.
37. Carpenter T.O. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 2005; 90: 1012–1020.
38. Sitara D. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am. J. Pathol. 2006; 169:2161–2170.
39. Makoto K. Klotho in chronic kidney disease – What’s new? Nephrol. Dial. Transplant. 2009; 24(6): 1705–1708.
40. Sitara D. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23:421–432.
41. Moe S.M., Duan D., Doehle B.P. et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003; 63:1003–1011.
42. Huang Chou-Long. Regulation of ion channels by secreted Klotho: mechanisms and implications. Kidney Int. 2010; 77: 855–860.
43. Masuyama R. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 2006; 116:3150–3159.
44. Darry L.J. Endocrine function of bone in mineral metabolism. Clin. Invest. 2008; 118(12): 3820–3828.
45. Block G.A., Brillhart S.L., Persky M.S. et al. Efficacy and safety of SBR759, a new iron-based phosphate binder. 2010; 77: 897–901.
46. Reddy V., Symes F., Sethi N. et al. Dietitian-Led Education Program to Improve Phosphate Control in a Single-Center Hemodialysis Population. 2009; 4(19): 314–320.
47. Волгина Г.В. Вторичный гиперпаратиреоз при хронической почечной недостаточности. Лечение активными метаболитами витамина D. Нефрол. диал. 2004; 2(6): 116–127.
48. Yamazaki Y. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 2008; 23: 1509–1518.
49. Shanahan C.M., Cary N.R.B., Metcalfe J.C., et al. High expression of genes for calcification-regulating proteins in human atherosclerotic placques. J. Clin. Invest. 1994; 93:2393–2402.
50. Slinin Y., Foley R.N., Collins A.J. Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study. J. Am. Soc. Nephrol. 2005; 16:1788–1793.


Об авторах / Для корреспонденции


Милованова Л.Ю. – научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, к.м.н.;
Милованов Ю.С. – д.м.н., ведущий научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России. E-mail: yumil2010@rambler.ru;
Козловская Л.В. – профессор кафедры терапии и профболезней медико-профилактического факультета, ведущий научный сотрудник отдела нефрологии НИИ уронефрологии
и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.


Похожие статьи


Бионика Медиа